Published in Adv Ther on October 31, 2015
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? J Clin Med Res (2017) 0.77
Passive leg raising test with minimally invasive monitoring: the way forward for guiding septic shock resuscitation? J Intensive Care (2017) 0.75
Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr (1990) 25.24
Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol (1978) 13.02
Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol (2012) 2.32
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J (2003) 2.10
Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol (2014) 2.08
Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J (2014) 1.92
Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol (2005) 1.74
Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med (2006) 1.73
Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm (1979) 1.47
The kidney in heart failure. N Engl J Med (1977) 1.34
Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol (2005) 1.12
Diuretic treatment and diuretic resistance in heart failure. Am J Med (1999) 1.10
Bumetanide and furosemide. Clin Pharmacol Ther (1983) 1.01
Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther (1980) 0.94
Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure. Arq Bras Cardiol (2007) 0.93
Neuroendocrine and renal effects of intravascular volume expansion in compensated heart failure. Am J Physiol Regul Integr Comp Physiol (2001) 0.90
Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail (2000) 0.89
Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure. Int J Cardiol (2012) 0.89
Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites. Semin Nephrol (2011) 0.84
Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples. J Pharm Biomed Anal (2010) 0.83
Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J (1994) 0.80
Changes in natriuretic peptide and cytokine plasma levels in patients with heart failure, after treatment with high dose of furosemide plus hypertonic saline solution (HSS) and after a saline loading. Nutr Metab Cardiovasc Dis (2010) 0.80
Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. Eur J Heart Fail (2015) 0.80
Combination diuretic therapy in severe congestive heart failure. Drugs (1998) 0.80
Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure. Adv Ther (2000) 0.79
Prognostic significance of 123I-mIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. Eur Heart J Cardiovasc Imaging (2015) 1.50
Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail (2015) 0.87
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J (2017) 0.76
Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. Eur J Heart Fail (2015) 0.75
Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Fail (2017) 0.75
Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction. Intern Emerg Med (2015) 0.75
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail (2017) 0.75
Hot Topics in Primary Care: Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus. J Fam Pract (2017) 0.75